Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems... Show more
A.I.dvisor indicates that over the last year, PACB has been loosely correlated with TXG. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if PACB jumps, then TXG could also see price increases.
| Ticker / NAME | Correlation To PACB | 1D Price Change % | ||
|---|---|---|---|---|
| PACB | 100% | +9.18% | ||
| TXG - PACB | 52% Loosely correlated | +5.78% | ||
| BFLY - PACB | 52% Loosely correlated | -2.87% | ||
| QSI - PACB | 49% Loosely correlated | +6.03% | ||
| ILMN - PACB | 48% Loosely correlated | +5.57% | ||
| MASS - PACB | 46% Loosely correlated | +2.52% | ||
More | ||||
| Ticker / NAME | Correlation To PACB | 1D Price Change % |
|---|---|---|
| PACB | 100% | +9.18% |
| Medical/Nursing Services industry (139 stocks) | 2% Poorly correlated | -0.31% |
| Health Services industry (240 stocks) | 1% Poorly correlated | -0.00% |
a developer of sequencing system products to help scientists to resolve genetically complex problems
Industry MedicalNursingServices
PACB moved above its 50-day moving average on September 17, 2026 date and that indicates a change from a downward trend to an upward trend. In 37 of 38 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The 10-day moving average for PACB crossed bullishly above the 50-day moving average on September 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 79%.
The 50-day moving average for PACB moved above the 200-day moving average on October 16, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +16.30% 3-day Advance, the price is estimated to grow further. Considering data from situations where PACB advanced for three days, in 221 of 262 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
The Aroon Indicator entered an Uptrend today. In 117 of 138 cases where PACB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 85%.
The 10-day RSI Indicator for PACB moved out of overbought territory on October 08, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In 27 of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at 87%.
The Momentum Indicator moved below the 0 level on October 14, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PACB as a result. In 76 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
The Moving Average Convergence Divergence Histogram (MACD) for PACB turned negative on October 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 42 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PACB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
PACB broke above its upper Bollinger Band on October 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. PACB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 92 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 98 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: PACB's P/B Ratio (-20.028) is slightly lower than the industry average of (2.923). P/E Ratio (-5.095) is within average values for comparable stocks, (2.388). PACB's Projected Growth (PEG Ratio) (180.110) is very high in comparison to the industry average of (11.052). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (2.565) is also within normal values, averaging (40.124).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PACB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.